Research assesses ability of SARS‐CoV‐2‐neutralising mAbs to prevent COVID‐19

In a recent study published in the Cochrane Library, researchers searched multiple databases to identify randomized controlled trials (RCTs) that evaluated severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐neutralizing monoclonal antibodies (mAbs).

Related Keywords

Cochrane Ro ,Naeblys Shutterstock ,Cochrane Library ,Medical Literature Analysis ,Retrieval System Online ,Excerpta Medica Database ,Cochrane Rob ,Coronavirus Disease Covid 19 ,Research ,Cars ,Antibodies ,Coronavirus ,Hospital ,N Vitro ,Ortality ,Micron ,Placebo ,Prophylaxis ,Espiratory ,Ars Cov 2 ,Evere Acute Respiratory ,Evere Acute Respiratory Syndrome ,Yndrome ,